Trial Profile
A Randomized, Single-center, Double-Blind, Placebo-Controlled Phase 1 Study to Evaluate Safety and Pharmacokinetics of Single Subcutaneous Injection of MT203 in Healthy Adult Japanese and Caucasian Male Participants
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Namilumab (Primary)
- Indications Plaque psoriasis; Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Takeda
- 31 Aug 2018 Results (n=29) published in the International Journal of Clinical Pharmacology and Therapeutics
- 18 Mar 2017 Results presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.